Imvax Shares Positive Phase 2b Data for IGV-001 Glioblastoma Treatment and Plans FDA Meeting
Imvax; IGV-001; glioblastoma; Phase 2b trial; overall survival; FDA meeting; immunotherapy; clinical trial; glioblastoma treatment
Top Drug Regulator Richard Pazdur to Retire from FDA Amid Industry Concerns
Richard Pazdur; FDA; retirement; Center for Drug Evaluation and Research; drug regulation; Marty Makary; leadership turnover
Alkeus Pharmaceuticals Appoints Carlos Quezada-Ruiz as Chief Medical Officer
Alkeus Pharmaceuticals; Carlos Quezada-Ruiz; Chief Medical Officer; Stargardt disease; gildeuretinol; retinal diseases; ophthalmology; clinical research; biopharmaceutical leadership
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial on December 3, 2025
ADC Therapeutics; LOTIS-7; clinical trial update; ZYNLONTA; Phase 1b trial; loncastuximab tesirine; safety; efficacy; corporate webcast
Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy
Tessera Therapeutics; Regeneron; gene writing; TSRA-196; AATD; alpha-1 antitrypsin deficiency; gene therapy; partnership; investment
Lilly Slightly Lowers Self-Pay Prices for Single-Dose Vials of Zepbound
Eli Lilly; Zepbound; price cut; self-pay; single-dose vials; direct-to-consumer; LillyDirect; obesity drug; GLP-1
UK Agrees to Increase Drug Spending by 25% to Avoid US Pharma Tariffs
UK; United States; drug spending; pharmaceutical tariffs; trade deal; medicine pricing; Trump administration; pharma companies
Whitehawk Therapeutics Appoints Margaret Dugan as Chief Medical Officer
Whitehawk Therapeutics; Margaret Dugan; Chief Medical Officer; CMO; oncology; ADC; drug development; clinical trials; Novartis; Dracen Pharmaceuticals; Schrödinger
Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update
Rakovina Therapeutics; Q3 2025; financial results; net loss; research and development expenses; AI-powered drug discovery; ATR inhibitor; CNS penetration; corporate milestones; NanoPalm joint-venture; investment conference; DTC eligibility
RapidAI Deepens Partnership with Amazon AWS to Expand Clinical Imaging AI Deployment
RapidAI; Amazon Web Services; AWS; clinical AI; imaging AI; RSNA 2025; FDA clearance; Rapid Edge Cloud; healthcare AI; neurovascular AI; Lumina 3D